Related Party Transactions |
12 Months Ended |
---|---|
Dec. 31, 2023 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 16. Related Party Transactions Astellas is an equity investor in the Company and considered a related party. During the years ended December 31, 2023, 2022 and 2021, the Company recorded license and development revenue related to collaboration agreements with Astellas of $6.7 million, $32.5 million, and $130.4 million, respectively. During the years ended December 31, 2023, 2022 and 2021, the Company also recorded drug product revenue from Astellas of $18.8 million, $11.1 million, and $3.2 million, respectively. See Note 3, Collaboration Agreements, License Agreement and Revenues, for details. The Company’s expense related to collaboration agreements with Astellas was immaterial for each of the three years ended December 31, 2023. As of December 31, 2023 and 2022, accounts receivable from Astellas were $0.8 million and $1.5 million, respectively. As of December 31, 2023 and 2022, total deferred revenue from Astellas were $16.9 million and $40.3 million, respectively. As of December 31, 2023, the amount due to Astellas, included in accrued and other current liabilities, and other long-term liabilities, totaled $40.5 million. As of December 31, 2022, the amount due to Astellas, included in accrued and other current liabilities, was and $63.9 million. Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang’s equity. See Note 5, Equity method investment - Variable Interest Entity, for details. For the years ended December 31, 2023, 2022 and 2021, the net product revenue from sales to Falikang were $89.1 million, $71.2 million and $35.6 million, respectively. See the Product Revenue, Net section in Note 3, Collaboration Agreements, License Agreement and Revenues, for details. The other income from Falikang were immaterial for each of the three years ended December 31, 2023. For the years ended December 31, 2023, 2022 and 2021, the investment income (loss) in Falikang was $2.6 million, $1.6 million, and $1.0 million, respectively. During the year ended December 31, 2023, the Company received $2.3 million of dividend distribution from Falikang. As of December 31, 2023 and 2022, the Company’s equity method investment in Falikang were $5.3 million and $5.1 million, respectively. See Note 5, Equity method investment - Variable Interest Entity, for details. As of December 31, 2023 and 2022 accounts receivable, net, from Falikang were $5.2 million and $10.5 million, respectively. |